Zomedica Corp Quarterly Income Statements Chart
Quarterly
|
Annual
Zomedica Corp Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | ||||||||||||
| net revenue | 6,262,000 | 7,337,000 | 6,347,000 | 6,020,000 | 5,482,000 | 6,157,000 | 4,776,000 | 4,246,000 | 3,751,000 | 4,080,792 | 22,514 | 15,693 |
| yoy | 14.23% | 19.17% | 32.89% | 41.78% | 46.15% | 50.88% | 21113.47% | 26956.65% | ||||
| qoq | -14.65% | 15.60% | 5.43% | 9.81% | -10.96% | 28.92% | 12.48% | 13.20% | -8.08% | 18025.58% | 43.47% | |
| cost of revenue | 2,145,000 | 2,264,000 | 1,985,000 | 1,972,000 | 1,647,000 | 1,863,000 | 1,215,000 | 1,210,000 | 990,000 | 1,019,619 | 17,899 | 35,876 |
| gross profit | 4,117,000 | 5,073,000 | 4,362,000 | 4,048,000 | 3,835,000 | 4,294,000 | 3,561,000 | 3,036,000 | 2,761,000 | 3,061,173 | 4,615 | -20,183 |
| yoy | 7.35% | 18.14% | 22.49% | 33.33% | 38.90% | 40.27% | 77061.43% | -15142.36% | ||||
| qoq | -18.84% | 16.30% | 7.76% | 5.55% | -10.69% | 20.58% | 17.29% | 9.96% | -9.81% | 66230.94% | -122.87% | |
| gross margin % | 65.75% | 69.14% | 68.73% | 67.24% | 69.96% | 69.74% | 74.56% | 71.50% | 73.61% | 75.01% | 20.50% | -128.61% |
| expenses | ||||||||||||
| general and administrative | 8,625,000 | 9,052,000 | 6,115,000 | |||||||||
| research and development | 1,771,000 | 3,099,000 | 867,000 | 859,000 | 918,000 | 777,000 | 1,131,000 | 319,000 | 351,000 | 664,905 | 288,453 | 270,674 |
| selling and marketing | 4,107,000 | 4,311,000 | 3,328,000 | |||||||||
| income from operations | -10,386,000 | -11,389,000 | -5,948,000 | -6,742,000 | -7,512,000 | -5,136,000 | -6,592,000 | -5,880,000 | -4,314,000 | -5,758,860 | -6,408,220 | -5,328,586 |
| yoy | 38.26% | 121.75% | -9.77% | 14.66% | 74.13% | -10.82% | 2.87% | 10.35% | ||||
| qoq | -8.81% | 91.48% | -11.78% | -10.25% | 46.26% | -22.09% | 12.11% | 36.30% | -25.09% | -10.13% | 20.26% | |
| operating margin % | -165.86% | -155.23% | -93.71% | -111.99% | -137.03% | -83.42% | -138.02% | -138.48% | -115.01% | -141.12% | -28463.27% | -33955.18% |
| interest income | 1,093,000 | 1,149,000 | 1,437,000 | 1,460,000 | 1,412,000 | 1,305,000 | 1,012,000 | -277,000 | -107,000 | -95,891 | -94,302 | -112,107 |
| interest expense | -64,000 | -62,000 | -50,000 | 6,054 | ||||||||
| gain on disposal of assets | ||||||||||||
| other income | 84,000 | -115,000 | 2,195,000 | 1,000 | -5,000 | 1,000 | ||||||
| foreign exchange loss | -129,000 | -13,500 | -45,000 | -26,000 | -29,000 | -67,000 | 7,000 | 24,570 | 5,609 | |||
| income before income taxes | -9,326,000 | -21,947,000 | -2,411,000 | -5,326,000 | -6,177,000 | -3,858,000 | -5,652,000 | -5,655,000 | -4,215,000 | -3,773,294.5 | -6,345,687 | -4,710,674 |
| income tax (benefit) expense | -166,000 | |||||||||||
| net income | -9,160,000 | -22,406,000 | -491,000 | -5,249,000 | -6,385,000 | -2,809,000 | -4,995,000 | -5,273,000 | -3,937,000 | |||
| yoy | 43.46% | 697.65% | -90.17% | -0.46% | 62.18% | |||||||
| qoq | -59.12% | 4463.34% | -90.65% | -17.79% | 127.31% | -43.76% | -5.27% | 33.93% | ||||
| net income margin % | -146.28% | -305.38% | -7.74% | -87.19% | -116.47% | -45.62% | -104.59% | -124.19% | -104.96% | 0% | 0% | 0% |
| unrealized gain, change in fair value of available-for-sale securities, net of tax | -11,000 | 416,000 | 244,000 | -8,000 | ||||||||
| change in foreign currency translation | -52,000 | 17,000 | -19,000 | -47,000 | 3,000 | 45,000 | -32,000 | -40,000 | 51,000 | |||
| net income and comprehensive loss | -9,223,000 | -21,973,000 | -266,000 | -5,304,000 | -6,099,000 | -2,830,000 | -5,830,000 | -5,313,000 | -3,886,000 | -3,773,294.5 | -6,345,687 | -4,710,674 |
| weighted-average number of common shares - basic and diluted | 979,949,668,000 | 979,949,668,000 | 979,949,668,000 | 979,949,668,000 | 979,949,668,000 | 979,924,052,000 | 979,946,407,000 | 979,899,668,000 | 979,899,668,000 | 956,533,761 | 978,494,076 | 973,656,518 |
| loss per share - basic and diluted | -0.009 | -0.023 | -0.001 | -0.005 | -0.007 | -0.006 | -0.005 | -0.005 | -0.004 | -0.01 | -0.005 | |
| income tax benefit | 459,000 | -1,920,000 | -77,000 | 208,000 | 1,049,000 | 657,000 | -382,000 | -278,000 | ||||
| selling, general and administrative | 9,931,000 | 10,429,000 | 8,653,000 | 9,022,000 | 8,597,000 | 6,724,000 | 8,155,128 | 6,124,382 | 5,037,729 | |||
| foreign exchange gain | 17,000 | 52,000 | -525 | |||||||||
| other loss | -1,000 | 22,196 | ||||||||||
| unrealized gains, change in fair value of available-for-sale securities, net of tax | 283,000 | |||||||||||
| loss on disposal of assets | -21,113 | 26,760 | ||||||||||
| unrealized losses, change in fair value of available-for-sale securities, net of tax | -66,000 | -803,000 | ||||||||||
| other (income) loss | -1,000 | |||||||||||
| gain on extinguishment of debt | -533,414 | |||||||||||
| other gains | -620.25 | -600 | ||||||||||
| income tax expense | ||||||||||||
| (gain) loss on disposal of assets | -116 |
We provide you with 20 years income statements for Zomedica Corp stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zomedica Corp stock. Explore the full financial landscape of Zomedica Corp stock with our expertly curated income statements.
The information provided in this report about Zomedica Corp stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.